Immunologic Shiftings
Jose Luiz M. Rios, MD. PhD 1,2 , Fabio C. Kuschnir 3 , Alfredo Alves Neto 4,5 , Flavia C. Loyola 4,5 , Mary A. da Venda 5,6 , Cristiane A. Iraha 4,5 , Joao B. M. Rios 4,5 ; 1 Petropolis Medicine Faculty -FASE, Petropolis, Brazil, 2 Policlinica Geral Do Rio de Janeiro, Rio de Janeiro, Brazil, 3 Pediatrics, Rio de Janeiro State University, Rio de Janeiro, Brazil, 4 Policlinica Geral do Rio de Janeiro, Brazil, 5 Petropolis Medicine Faculty -FASE, 6 Policlinica Geral Do Rio de Janeiro, Rio de Janeiro, Brazil. RATIONALE: Patients with anaphylactic cow's milk allergy (CMA) have persistent and high levels of specific IgE (sIgE) to milk proteins. The purpose of this research was follow-up these and other parameters during the induction phase of CM OIT. METHODS: Series of cases involving 30 children and adolescents with anaphylaxis to CM. SIgE levels were evaluated in 2 steps of OIT: at baseline, pre-treatment session (step 1) and when reaching the induction final volume: 150 ml of CM a day (step 2). Time between steps lasted 4 to 6 months. Differences between sIgE levels were analyzed by Paired Student's t test. RESULTS: The sample mean age was 8.9 years (min: 4 -max: 20). At step 1, sIgE mean levels for CM, casein , a-lactoalbumin and b-lactoglobulin were respectively, in KU/L: 57.05 (9.0 ->100.0); 48.54 (7.0 ->100); 27.10 (1.0 ->100) and 16.48 (2.3 -83.7). Besides the mean level of total IgG4 was 141.76 KU/l (6.25 -966.0). At step 2 these values were respectively: 32.12 (0.32 ->100); 24.05 (0.10 -77.3); 21.01 (0.10 -> 100) and 11.08 (1.0 -46.5). And the total IgG4 mean was 234.87 (0.10 -1020.0). Comparing sIgE and IgG4 means between the steps revealed statistical significance for CM (p<0.001); casein ( p<0.001) and b -lactoglobulin (p50.04); besides IgG4 (p50,03). CONCLUSIONS: In few months CMA-OIT reduces sIgE levels for milk proteins in parallel to developing clinical tolerance to milk ingestion.
Increase of total IgG4 levels could manifest increase in specific IgG4 for CM proteins and signal OIT success.
430 Real-Life Follow-up in Cows Milk Immunotherapy:
Clinical and Serological Data
Paloma Poza-Guedes, MD 1 , Ruperto Gonz alez-P erez, MD, PhD 1 , Inmaculada Sanchez-Machin, MD 2 , Victor Matheu, MD, PhD 2 ; 1 Hospital del T orax-Ofra, Sta Cruz de Tenerife, Spain, 2 Hospital Universitario de Canarias, La Laguna, Spain. RATIONALE: Although oral milk inmunotherapy (OMI) is becomig widely extended as a promising therapy in patients with persistent cow's milk allergy (CMA), there is relative scarce experience in real-life clinical practice. METHODS: We selected patients with persistent CMA and uncontrolled symptoms despite a strict restrictive diet. We performed a 2-step OMI protocol: first phase (desensitization) in the Allergy clinic, a weekly scheduled protocol individualy adjusted according to clinical tolerance, from diluted milk (1:10) to reach the final dose (250 ml undiluted milk). A second phase of ambulatory clinical follow-up were performed every 6 months during 5 years. Clinical and serological data (specific-IgE and IgG4) were collected after every visit. RESULTS: Thirty two children (2-17 y.o.) fully completed OMI reaching the final dose. All patients performed the total clinical follow-up during 5 years, although significative adverse reactions were recorded only in the first 2 years. Relevant serological changes were obtained both at the initial phase (first year) and the long-term evolution. All patients were able to have a free cow s milk diet, and only 3 subjects had persistent goat s milk allergy. CONCLUSIONS: OMI requires a highly skilled staff but offers encouraging results in the long-term follow-up. Milk allergic patients may benefit from food immunotherapy but an accurate and individual diagnosis is mandatory. OMI protocols must be a custom-designed procedures to reach the desired outcomes. RATIONALE: In patients with severe cow's milk allergy, desensitization in combination with Omalizumab could be an alternative that improves the patient s quality of life and reduces the risk of allergic reactions. METHODS: We present 4 patients, with mild-moderate persistent allergic asthma, 50% males (age:10-12 years) who suffered immediate reactions after ingestion of milk (one of them required intubation and ICU admission). Patients were diagnosed of milk allergy by positive skin prick tests and specific IgE: Casein>100 kU/L with total IgE:518-1040 IU/ml. We selected these subjects because of: One with asthma poorly controlled, another one with a nearly fatal reaction, and two with unsuccesful previous desensitization to milk. We treated them with Omalizumab during 16 weeks prior to desensitization. The adjusted dose by weight and total IgE were 300-450mg every 15-28 days. During the procedure patients received their usual asthma treatment (inhalers and montelukast) with cetirizine as pretreatment. The desensitization procedure began with milk at 1/10.000 dilutions up to 250 ml of milk over a 12 weeks period. The weekly increases were performed at Allergy Unit, later the same maintenance dose was given daily at home. RESULTS: Three of them achieved total tolerance to milk without reactions. The other one reached only good tolerance to 180 ml of milk from which moderate allergic reactions appeared. All patients follow with the same dose of Omalizumab, well tolerated, two of them take cetirizine too. CONCLUSIONS: Omalizumab is effective for desensitization to milk. It could be used when conventional desensitization regimen is not successful or in high-risk patients.
